Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Vaughan

Showing results (41-50 of 1,036) with videos related to

Pageof 104
Sort By:
Cellular Signalling|July 1, 1993
ADP-ribosylation factors, 20,000 M(r) guanine nucleotide-binding protein activators of cholera toxin and components of intracellular vesicular transport systemsJ Moss, M Vaughan
Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology|January 1, 1975
Classification of antidysrhythmic drugsE M Vaughan Williams
Methods in Enzymology|January 1, 1984
NAD: arginine mono-ADP-ribosyltransferases from animal cellsJ Moss, M Vaughan
Annals of the New York Academy of Sciences|January 1, 1984
DisopyramideE M Vaughan Williams
Journal of Clinical Pharmacology|April 1, 1984
A classification of antiarrhythmic actions reassessed after a decade of new drugsE M Vaughan Williams
Journal of Clinical Pharmacology|February 1, 1991
Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trialE M Vaughan Williams
Current Topics in Cellular Regulation|January 1, 1992
Activation of cholera toxin by ADP-ribosylation factors, 20-kDa guanine nucleotide-binding proteinsJ Moss, M Vaughan
Journal of Cardiovascular Pharmacology|January 1, 1985
Cardiac electrophysiological effects of selective adrenoceptor stimulation and their possible roles in arrhythmiasE M Vaughan Williams
Journal of Clinical Pharmacology|July 1, 1987
Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actionsE M Vaughan Williams
Journal of Clinical Pharmacology|November 1, 1992
Classifying antiarrhythmic actions: by facts or speculationE M Vaughan Williams
Pageof 104

Showing results (41-50 of 1,036) with videos related to

Sort By:
Pageof 104
Cellular Signalling|July 1, 1993
ADP-ribosylation factors, 20,000 M(r) guanine nucleotide-binding protein activators of cholera toxin and components of intracellular vesicular transport systemsJ Moss, M Vaughan
Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology|January 1, 1975
Classification of antidysrhythmic drugsE M Vaughan Williams
Methods in Enzymology|January 1, 1984
NAD: arginine mono-ADP-ribosyltransferases from animal cellsJ Moss, M Vaughan
Annals of the New York Academy of Sciences|January 1, 1984
DisopyramideE M Vaughan Williams
Journal of Clinical Pharmacology|April 1, 1984
A classification of antiarrhythmic actions reassessed after a decade of new drugsE M Vaughan Williams
Journal of Clinical Pharmacology|February 1, 1991
Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trialE M Vaughan Williams
Current Topics in Cellular Regulation|January 1, 1992
Activation of cholera toxin by ADP-ribosylation factors, 20-kDa guanine nucleotide-binding proteinsJ Moss, M Vaughan
Journal of Cardiovascular Pharmacology|January 1, 1985
Cardiac electrophysiological effects of selective adrenoceptor stimulation and their possible roles in arrhythmiasE M Vaughan Williams
Journal of Clinical Pharmacology|July 1, 1987
Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actionsE M Vaughan Williams
Journal of Clinical Pharmacology|November 1, 1992
Classifying antiarrhythmic actions: by facts or speculationE M Vaughan Williams
Pageof 104